Almac Diagnostics discusses new biomarker service

By Gareth Macdonald

- Last updated on GMT

Related tags: Pharmacology

Almac says an effective biomarker strategy boosts a drug candidates’ chance of success and can ultimately add value to a developer’s business by opening door to diagnostics.

Earlier this month Almac’s diagnostics arm launched a new biomarker development service which, as VP of business development Michael Sloan told Outsourcing-pharma, is intended to cater for growing biopharmaceutical manufacturing sector demand.

Sloan explained that demand for pharmacodynamic biomarkers, as well as those for clinical trial enrichment, is increasing day by day as everyone from Big Pharma to biotech recognises their value in the drug development process.

He also suggested that, increasingly, such companies are adopting broader strategies involving commercial development of biomarkers for in clinic diagnostics purposes which, while a new market, is one in which he sees considerable growth potential.

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more